30 closest matches · ranked by relevance
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 14.2; 4.4 Months
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Objective Response Rate (CR or PR) According to RECIST Criteria — 5 percentage of patients responding
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Lung Cancer
Primary: Overall Objective Response — 1; 1; 3; 2 participants
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
Lung Cancer
Primary: Progression Free Survival(PFS) — 5.6 months
Lung Cancer
Primary: Overall Response Rate — 18; 34; 28 percentage of participants
Stage IIIB Lung Non-Small Cell Cancer AJCC v7 · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression Free Survival (PFS) — 4.3; 2.6 months — p=0.0006
Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma · Lung Adenocarcinoma
Primary: PFS (Progression Free Survival) — 8; 20 months
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIB Non-Small Cell Lung Cancer AJCC v7 · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: 18 Week Progression-free Survival (PFS) Rate — 54; 37; 48 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT — 65.2 percentage of participant with DC
Lung Cancer · SCLC
Primary: Phase I: Maximum Tolerated Dose (MTD) — 30 mg/m^2
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) — 30; 50; 58.8; 30.3 Percent of Participants
Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) — 1; 12; 17 participants
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Time to Progression — 4.63 months
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Stage IV Non-Small Cell Lung Cancer
Primary: Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung…
Lung Cancer
Primary: Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008]) — 0; 0; 2 DLTs